318 related articles for article (PubMed ID: 26285457)
21. Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.
Wang FP; Xiong XF; Liu T; Li SY; Cheng DY; Mao H
Clin Rev Allergy Immunol; 2018 Apr; 54(2):318-330. PubMed ID: 27677499
[TBL] [Abstract][Full Text] [Related]
22. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
23. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
24. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
25. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
[No Abstract] [Full Text] [Related]
26. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
27. Prediction of response to biological treatment with monoclonal antibodies in severe asthma.
Kroes JA; Zielhuis SW; van Roon EN; Ten Brinke A
Biochem Pharmacol; 2020 Sep; 179():113978. PubMed ID: 32305434
[TBL] [Abstract][Full Text] [Related]
28. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
29. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
30. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis.
He LL; Zhang L; Jiang L; Xu F; Fei DS
Int Immunopharmacol; 2018 Nov; 64():223-231. PubMed ID: 30199847
[TBL] [Abstract][Full Text] [Related]
32. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Han D; Lee JK
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
[No Abstract] [Full Text] [Related]
33. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
[TBL] [Abstract][Full Text] [Related]
34. Severe asthma: what is new in the new millennium.
Ntontsi P; Samitas K; Zervas E; Gaga M
Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
Giannetti MP; Cardet JC
Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
[TBL] [Abstract][Full Text] [Related]
37. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
38. Matching-adjusted indirect comparison of benralizumab
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
[TBL] [Abstract][Full Text] [Related]
39. Mepolizumab: A Review in Eosinophilic Asthma.
Deeks ED
BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
